Synthetic organic

AZ3971.

AZ4800.

AZ4800.

AZ505.

AZ505.

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

InformationAZ5104, the demethylated metabolite of AZD-9291, is a potentEGFRinhibitor withIC50of &lt:1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.TargetsEGFR (L858R/T790M)

AZ7188.